Jaguar Health, Inc. (JAGX) is a commercial stage pharmaceuticals company based in San Francisco, California, engaged in the development and commercialization of novel, plant-based, non-opioid, and sustainable prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhoea. It is publicly traded on Nasdaq under the symbol JAGX.
The company’s proprietary, patent-protected Mytesi® (crofelemer) product, the core ingredient of which comes from the latex of the South American tree known as Croton lechleri, is approved by the U.S FDA for treating noninfectious diarrhoea in adult patients with HIV/AIDS who are on anti-retroviral therapy. Crofelemer is a unique, first-in-class, ionic, molecular “normalizer” that works locally in the gut to regulate both the secretion and absorption of chloride and sodium ions and effectively treats chronic diarrhoea.
Beyond HIV, Jaguar Health is exploring other opportunities for Mytesi®, such as possible indications for cancer therapy-related diarrhoea, diarrhoea related to long-hauler COVID-19 syndrome, orphan-drug indications for short bowel syndrome (SBS), and congenital diarrheal disorders (CDD).
Jaguar Health's wholly-owned subsidiary in Italy, Naples BioSciences Srl, is focused on the discovery of sustainable plant-based compounds for potential indications of inflammatory, infectious, and GI diseases.
Jaguar Health, Inc. takes a keen interest in sustainability and environmental responsibility. The company works with local communities in the Amazon Rainforest to ensure ethical procurement of the raw latex used in its products, providing a sustainable economic activity that doesn't harm the forest. Meanwhile, the company runs animal health studies through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
Jaguar Health is led by a seasoned management team with a strong track record in gastrointestinal disorders and has collaborations with leading research institutions, making it a potent contender in the biopharmaceutical industry. The successful application of its proprietary technology to new indications could present significant growth opportunities for the company in the years to come.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Jaguar Health (JAGX) stock rose significantly due to optimism surrounding its rare-disease pipeline, particularly its crofelemer drug for pediatric intestinal failure. The company is advancing towards a mid-2027 NDA filing for microvillus inclusion disease (MVID) and has reported positive real-world data showing significant reductions in IV nutrition needs for MVID and short bowel syndrome patients. Additionally, FDA user-fee waivers and the expansion of its animal-health franchise contribute to the positive outlook, despite the company's current negative profit margins and cash flow.
Jaguar Health Inc. (NASDAQ: JAGX) shares surged on Friday, reversing a previous sell-off, after the company announced further debt-for-equity exchanges. These transactions reduced its outstanding debt by over $6.7 million, fully retiring a major promissory note. This move improves the company's liquidity and capital structure, supporting the commercialization of Mytesi and funding clinical trials for crofelemer.
Jaguar Health (JAGX) stock collapsed by 59% due to apparent profit-taking after a significant run, while Viking Therapeutics (VKTX) fell 4% following positive obesity drug trial data, marking a pullback. Both declines are company-specific, occurring in a biotech sector that remains largely stable, suggesting no broader market sell-off. Investors should monitor whether Viking Therapeutics stabilizes after its data is digested and if Jaguar Health finds a floor.
Jaguar Health Inc. (NASDAQ: JAGX) shares plunged on Wednesday due to profit-taking after a significant rally driven by a regulatory fee waiver and low-float volatility. The stock's dramatic surge was amplified by a recent 1-for-15 reverse stock split, which restricted its public float. The company also faces persistent financial challenges, including a net loss of $12.7 million in Q2 and over $25 million in current liabilities, leading to a planned secondary securities offering.
Jaguar Health, Inc. announced that its family company, Napo Pharmaceuticals, received a fee waiver from the FDA for the Prescription Drug User Fee Act (PDUFA) for Mytesi for the 2027 fiscal year. Additionally, Jaguar Health was granted a fee waiver by the Center for Veterinary Medicine of the FDA for Canalevia-CA1 for the 2027 fiscal year. The company remains focused on its rare disease intestinal failure global development program, targeting an NDA filing for MVID by mid-2027.